Screener
Sana Biotechnology SANA Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Fees related to common stock financings, net | (96) | (60) |
| Principal payments, net for tenant improvement loan | (91) | (85) |
| Net cash provided by (used in) financing activities | (128) | 982 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 11,930 | (31,072) |
| Cash, cash equivalents, and restricted cash at beginning of period | 76,065 | 131,398 |
| Cash, cash equivalents, and restricted cash at end of period | $87,995 | $100,326 |
| SUPPLEMENTAL CASH FLOW INFORMATION: | ||
| Cash received for tenant improvement allowances | - | $891 |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's net change in cash?
- Sana Biotechnology (SANA) reported net change in cash of $11.93M in Q1 2026.
- How has Sana Biotechnology's net change in cash changed year-over-year?
- Sana Biotechnology's net change in cash increased by 138.4% year-over-year, from -$31.07M to $11.93M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Sana Biotechnology's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude